- CIN
- —
- ISIN
- INE0DJ201029
- Incorporated
- —
- Registered state
- —
Key valuation
- Market cap
- ₹10,730 Cr
- P/E
- —
- Debt / equity
- 0.6x
- Shares outstanding
- 17,03,24,95,304
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Price history
Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.
Business overview
Most people know this one as PharmEasy. The parent company is API Holdings, incorporated on 31 March 2019, running a digital healthcare business through a stack of subsidiaries that covers technology, pharmaceutical distribution, diagnostics and health services. PharmEasy is the consumer facing part, where you order prescription medicines, OTC products and wellness items and they arrive at your door. Behind it sits a services layer, call centre operations, medical and legal transcription, data processing, warehousing, logistics and database management. The group grew mostly by buying things. Around 26 subsidiaries now, Docon and Thyrocare among them, and Thyrocare is a name plenty of people will recognise from a blood test slip. Pharmacy, diagnostics and teleconsultation under one roof is the shape they are working toward.
Key highlights
- Incorporated in 2019
Financial snapshot
FY2025
- Revenue FY2025
- ₹5,872.16 Cr
- EBITDA
- ₹-949.66 Cr
- PAT
- ₹-1,572.39 Cr
- Net worth
- ₹3,272.28 Cr
- Total debt
- ₹2,033.67 Cr
- Cash & equivalents
- ₹118.99 Cr
- Operating cash flow
- ₹-223.53 Cr
- EPS
- ₹-0.92
Reported financials · FY2021–FY2025
Figures in ₹ crore unless stated.
| Particulars | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY | CAGR |
|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||
| Revenue from operationsYoY +3.7%CAGR +25.9% | 2,335 | 5,729 | 6,644 | 5,664 | 5,872 | +3.7% | +25.9% |
| Other income | 25 | 52 | 56 | 95 | 108 | — | — |
| Total expenses | 2,905 | 8,492 | 8,974 | 7,255 | 7,209 | — | — |
| EBITDA | -595 | -2,346 | -4,343 | -1,673 | -950 | — | — |
| Depreciation & amortisation | 33 | 159 | 243 | 216 | 169 | — | — |
| EBIT | -628 | -2,505 | -4,587 | -1,889 | -1,119 | — | — |
| Finance cost | 43 | 258 | 666 | 728 | 506 | — | — |
| Profit before tax | -620 | -3,971 | -5,197 | -2,522 | -1,517 | — | — |
| Tax expense | 21 | 22 | 15 | 12 | 56 | — | — |
| Profit after tax | -641 | -3,993 | -5,212 | -2,534 | -1,572 | — | — |
| Earnings per share | ₹-0.38 | ₹-2.34 | ₹-3.06 | ₹-1.49 | ₹-0.92 | — | — |
| Balance sheet | |||||||
| Net worthYoY +26.4%CAGR -2.2% | 3,581 | 7,022 | 2,437 | 2,588 | 3,272 | +26.4% | -2.2% |
| Total debt | 5 | 2,585 | 4,120 | 4,098 | 2,034 | — | — |
| Current liabilities | 111 | 3,762 | 2,323 | 3,502 | 1,781 | — | — |
| Cash & equivalents | 230 | 157 | 194 | 328 | 119 | — | — |
| Current assets | 1,736 | 2,502 | 2,535 | 3,476 | 2,513 | — | — |
| Total assetsYoY -16.8%CAGR +9.2% | 4,905 | 11,398 | 8,256 | 8,390 | 6,977 | -16.8% | +9.2% |
| Cash flow | |||||||
| Operating activities | -179 | -2,589 | -744 | -61 | -224 | — | — |
| Investing activities | -954 | -5,789 | -72 | -1,261 | 775 | — | — |
| Financing activities | 1,119 | 8,305 | 853 | 1,457 | -760 | — | — |
| Net change in cash | -15 | -73 | 37 | 135 | -208 | — | — |
Revenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.
Valuation multiples
What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹6.30 indicative price.
- Market cap
- ₹10,730 Cr
- Enterprise value
- ₹12,645 Cr
- Price / book (P/B)
- 3.28x
- Price / sales (P/S)
- 1.83x
- EV / sales
- 2.15x
- Earnings yield
- -14.7%
- Cash / market cap
- 1.1%
How these are worked out
- Market cap
- Indicative price × shares outstanding
- Enterprise value
- Market cap + debt − cash
- Price / book (P/B)
- Market cap ÷ net worth
- Price / sales (P/S)
- Market cap ÷ revenue from operations
- EV / sales
- Enterprise value ÷ revenue from operations
- Earnings yield
- PAT ÷ market cap
- Cash / market cap
- Cash & equivalents ÷ market cap
IPO / listing status
The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.
Research & news
Information currently unavailable
Nothing has been published on Pharmeasy yet. Research, news and articles tagged with it will appear here when they are.
Documents
Information currently unavailable
No documents have been catalogued for this company yet.